Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NTLA
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want ...
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want ...
Yahoo Finance4d
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025
We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...
Yahoo Finance5d
Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025
In this article, we are going to take a look at where Intellia Therapeutics Inc. (NASDAQ:NTLA) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall Street's most ...
Finanznachrichten8d
Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Hosted on MSN16d
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)
Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...
Seeking Alpha29d
Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)
Intellia Therapeutics (NASDAQ:NTLA) did it again. On January 9, 2025, the company announced it would discontinue efforts on NTLA-3001, one of its pipeline gene-editing treatments. It also said it ...